2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Xanthine Oxidase
  5. Xanthine Oxidase Inhibitor

Xanthine Oxidase Inhibitor

Xanthine Oxidase Inhibitors (97):

Cat. No. Product Name Effect Purity
  • HY-139585
    Tigulixostat
    		Inhibitor 99.18%
    Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia.
  • HY-N0358
    1,4-Dicaffeoylquinic acid
    		Inhibitor 98.44%
    1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid compound that can be isolated from Xanthii fructus and an inhibitor of xanthine oxidase (IC50: 7.36 μM). 1,4-Dicaffeoylquinic acid has anti-inflammatory activity and can inhibit the production of TNF-α induced by LPS (HY-D1056).
  • HY-N8600
    7,8,3′,4′-Tetrahydroxyflavone
    		Inhibitor 99.51%
    7,8,3′,4′-Tetrahydroxyflavone (compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 value of 10.488 µM.
  • HY-W037417
    DAO-IN-1
    		Inhibitor
    DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO) with an IC50 value of 269 nM. DAO is an enzyme responsible for D-serine metabolism, D-serine is a co-agonist of NMDA receptors.
  • HY-B0219A
    Allopurinol sodium
    		Inhibitor 99.88%
    Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect.
  • HY-N9330
    Broussoflavonol F
    		Inhibitor 98.11%
    Broussoflavonol F possess xanthine oxidase inhibitory activity.
  • HY-153968
    URAT1&XO inhibitor 1
    		Inhibitor 99.96%
    URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research.
  • HY-B0219S
    Allopurinol-d2
    		Inhibitor 98.36%
    Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect[1][2].
  • HY-14268S
    Febuxostat-d9
    		Inhibitor 98.70%
    Febuxostat-d9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with a Ki of 0.6 nM.
  • HY-131268
    O-Desisobutyl-O-n-propyl Febuxostat
    		Inhibitor
    O-Desisobutyl-O-n-propyl Febuxostat, extracted from the patent CN 103467412, is an xanthine oxidase inhibitor.
  • HY-153972
    URAT1&XO inhibitor 2
    		Inhibitor 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
  • HY-14669
    Niraxostat
    		Inhibitor 98.54%
    Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved.
  • HY-B0219R
    Allopurinol (Standard)
    		Inhibitor
    Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect.
  • HY-W008550
    8-Azaadenine
    		Inhibitor 99.69%
    8-Azaadenine is a Xanthine Oxidase inhibitor (IC50 = 0.54 μM).
  • HY-19657S
    Oxypurinol-13C,15N2
    		Inhibitor
    Oxypurinol-13C,15N2 is 15N and 13C labeled Oxypurinol (HY-19657). Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
  • HY-14268A
    Febuxostat sodium
    		Inhibitor
    Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout.
  • HY-162910
    HDAC-IN-79
    		Inhibitor
    HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
  • HY-146273
    Xanthine oxidase-IN-7
    		Inhibitor
    Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC50 of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout.
  • HY-151975
    Xanthine oxidoreductase-IN-5
    		Inhibitor
    Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor, with an IC50 of 55 nM. Xanthine oxidoreductase-IN-5 can be used for the research of acute hyperuricemia.
  • HY-150257A
    Xanthine oxidase-IN-11
    		Inhibitor
    Xanthine oxidase-IN-11 (XO8 analog) is an xanthine oxidase (XO) inhibitor.